AXSOME THERAPEUTICS, INC. Gain (Loss) on Extinguishment of Debt
AXSOME THERAPEUTICS, INC. (AXSM) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$10.38M.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was -$10.38M.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2020 was -$1.25M.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2015 was -$2.44M.
- AXSOME THERAPEUTICS, INC. gain (loss) on extinguishment of debt for fiscal 2014 was -$2.87M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | -$10.38M derived: sum of 3 quarters · filed 2026-08-10 | -$10.38M 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$10.38M derived: sum of 2 quarters · filed 2026-08-10 | -$10.38M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | -$10.38M 10-Q · filed 2026-08-10 | -$10.38M 10-Q · filed 2026-08-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.25M derived: sum of 2 quarters · filed 2023-02-28 | -$1.25M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$1.25M 10-Q · filed 2021-11-08 | -$1.25M 10-Q · filed 2021-11-08 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$2.44M derived: sum of 2 quarters · filed 2018-03-07 | -$2.44M 10-K · filed 2018-03-07 | |
| 2015-09-30 | -$2.44M 10-Q · filed 2016-11-14 | -$2.44M 10-Q · filed 2016-11-14 | ||
| 2014-12-31 | -$2.87M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |